Aim To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis. Methods Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80kg or 80kg) and BMI (healthy, BMI 22 - 24.99kg/m(2); overweight, BMI 25 - 29.99kg/m(2); obese, BMI 30kg/m(2)). Results The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n=12) compared with healthy weight (n=33) or overweight (n=21) patients. Conclusion Obesity has a negative effect on the efficacy of etanercept in psoriasis.
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
Esposito M
2016-01-01
Abstract
Aim To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis. Methods Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80kg or 80kg) and BMI (healthy, BMI 22 - 24.99kg/m(2); overweight, BMI 25 - 29.99kg/m(2); obese, BMI 30kg/m(2)). Results The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n=12) compared with healthy weight (n=33) or overweight (n=21) patients. Conclusion Obesity has a negative effect on the efficacy of etanercept in psoriasis.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
